These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11353638)

  • 1. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.
    Livermore DM; Carter MW; Bagel S; Wiedemann B; Baquero F; Loza E; Endtz HP; van Den Braak N; Fernandes CJ; Fernandes L; Frimodt-Moller N; Rasmussen LS; Giamarellou H; Giamarellos-Bourboulis E; Jarlier V; Nguyen J; Nord CE; Struelens MJ; Nonhoff C; Turnidge J; Bell J; Zbinden R; Pfister S; Mixson L; Shungu DL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1860-7. PubMed ID: 11353638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
    Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
    Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.
    Livermore DM; Oakton KJ; Carter MW; Warner M
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2831-7. PubMed ID: 11557477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
    Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
    Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR; Sader HS; Stillwell MG; Jones RN
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control.
    Brown SD; Traczewski MM
    J Antimicrob Chemother; 2005 Jun; 55(6):944-9. PubMed ID: 15872043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
    Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.
    Aldridge KE
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):181-6. PubMed ID: 12458126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.